prIME Oncology's Virtual Expert Practice utilizes interactive video in the presentation of case-based discussions.  

Expert clinicians provide valuable insight into clinically relevant and contemporary topics in oncology.

This activity will provide you with the valuable information that can be readily applied to the daily management of patients with non-small cell lung cancer (NSCLC).

Chair Corey Langer, MD, FACP Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania United States

Faculty Nasser Hanna, MD Melvin and Bren Simon Cancer Center Indiana University Indianapolis, Indiana United States Walter Curran, MD, FACR Winship Cancer Institute Emory University Atlanta, Georgia United States

Module 1 - Interactive clinical case study #1:
Early stage lung cancer: Advances in adjuvant therapy
Corey Langer, MD, FACP
 
Module 2 - Interactive clinical case study #2:
Unresectable locally advanced NSCLC
Walter Curran, MD, FACR
 
Module 3 - Tools and guidance in therapy selection: Clinical and molecular biomarkers
Nasser Hanna, MD
 
Module 4 - Interactive clinical case study #3:
Individualizing therapy in metastatic NSCLC: Choosing the best options
Corey Langer, MD, FACP


Module 5 - Interactive clinical case study #4:
Advanced NSCLC: A patient with Bone metastases
Corey Langer, MD, FACP


Module 6 - Evaluating the next generation of targeted therapies
Nasser Hanna, MD

This educational activity is intended for medical oncologists, pulmonologists, pathologists, thoracic surgeons, and oncology nurses actively involved in the management of patients with non-small cell lung cancer.

To optimize outcomes in patients with lung cancer, there is an urgent need to address clinical knowledge gaps regarding the many recent scientific and treatment advances in this area. Because treatment of lung cancer is multimodal and multidisciplinary, educational opportunities on this topic will reach beyond medical oncologists to the broader oncology healthcare community.

Upon completion of this educational activity, participants should be able to:

• Identify contemporary approaches in the adjuvant therapy for resected NSCLC
• Appraise the potential utility of targeted agents in the management of unresectable locally advanced NSCLC

• Propose appropriate first-line and second-line management options for metastatic NSCLC, including the incorporation of approved and investigational therapeutic agents

• Appraise the potential utility of currently available and emerging targeted agents in the management of advanced NSCLC

• Identify currently available therapies and their impact on patients with bone metastases

• Integrate clinical and molecular markers in treatment decisions for individual patients

• Apply the practice-changing recent clinical trial data to daily clinical practice

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Dr Langer has disclosed that he has received consulting fees from Bristol-Myers Squibb; Eli Lilly and Company; Genentech BioOncology; OSI Pharmaceuticals; and sanofi-aventis.  He has also recieved fees for non-CME/CE services from Bristol-Myers Squibb; Eli Lilly and Company; and Genentech BioOncology. He has ownership interest in Genentech BioOncology; OSI Pharmaceuticals; and Pfizer Inc. none of these relationships will not impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Curran has disclosed that he has recieved consulting fees from Eli Lilly and Company; Genentech; GlaxoSmithKline; and ImClone Systems Incorporated. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hanna has disclosed that he has recieved consulting fees from AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Eli Lilly and Company; and Pfizer Inc. He also has other financial relationships with Celgene Corporation; and OSI Pharmaceuticals. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The following planners, reviewers, and managers of Postgraduate Institute for Medicine, Linda Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kirkwood, RN, BSN; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following planners and managers of prIME Oncology, Nathan Kelly, PhD (clinical), Trudy Stoddert, ELS (editorial), and Susan Ahn (project management) hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.